Developer docs
API playgroundTry for free, no card

Search company profiles

Oncotelic

Full company profile

uuid000b2vn

Namestring
Oncotelic
Legal namestring
Oncotelic Inc.
Websiteurl
oncotelic.com
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Oncotelic Inc. is a clinical-stage immuno-oncology company developing RNA therapeutics, small-molecule drugs, and nanomedicine delivery systems for cancer and infectious diseases, trading on the OTCQB under ticker OTLC. The lead therapeutic candidate, OT-101 (Trabedersen), is a phosphorothioate antisense oligodeoxynucleotide targeting TGF-β2 mRNA, currently in Phase 3 development for glioblastoma and Phase 2b/3 for pancreatic cancer (STOP-PC trial combining with mFOLFIRINOX). The company has secured three FDA Rare Pediatric Disease Designations (OT-101/DIPG, CA4P/melanoma, OXi4503/AML) and is advancing a Deciparticle nanomedicine platform with six nanoparticle candidates; Sapu003, an IV Deciparticle formulation of everolimus, entered a Phase 1b trial in May 2026 with the first patient dosed. Additional pipeline assets include CA4P (vascular disrupting agent), OXi4503, and AL-101/N2B intranasal nose-to-brain delivery for CNS disorders.

The company's differentiating technology layer is PDAOAI, an AI knowledge discovery platform indexing approximately 28 million PubMed abstracts refreshed daily on Qdrant vector infrastructure, using proprietary clustering, manifold folding, and shell-sampling methods (covered by PCT/US2024/057972) to identify upstream disease drivers rather than proximity matches. PDAOAI is also deployed as a robotics knowledge layer integrated with TechForce Robotics' PUR-E cleanroom robot and LIM-E logistics robot for GMP pharmaceutical manufacturing, where it automates batch-record execution through a Kebbi voice interface. The company operates through three entities: wholly-owned subsidiaries Sapu Bio and Sapu Nano, and a 45%-owned joint venture GMP Bio valued at over $1 billion enterprise value with planned Hong Kong IPO.

Oncotelic's revenue model is a mix of (i) future drug development licensing and royalty income from its therapeutic pipeline, (ii) AI-enabled GMP manufacturing services commercialized with TechForce Robotics targeting pharmaceutical manufacturers at subscription pricing tied to facility throughput, and (iii) equity value recognition from the GMP Bio JV. Currently the company has no disclosed product revenue — FY2025 net income of $249M was driven by a $365.4M non-cash JV revaluation gain — and operates as a pre-commercial biotech funded by equity rounds, most recently $12.5M in May 2026. GTM is enterprise B2B and event-driven, centered on BIO International Convention, AACR, SNO, and SITC conference presence to source partnership and licensing deals.

Short descriptiontext

Oncotelic is a clinical-stage immuno-oncology company developing TGF-β antisense (OT-101), Deciparticle nanomedicines (Sapu003), and the PDAOAI AI platform for drug discovery and GMP manufacturing automation, serving pharmaceutical manufacturers and oncology patients through licensing and partnership channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAgoura Hills, United States
HQ citystring
Agoura Hills
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-oncology therapeutics, antisense RNA therapeutics, nanomedicine drug delivery, AI drug discovery platform, GMP pharmaceutical manufacturing
Industry5 codes
PRIMARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Drug Development
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Manufacturing Services
TypeManaged Services
Description

Revenue from AI-powered GMP manufacturing services platform commercialized with TechForce Robotics, targeting pharmaceutical and biotech manufacturers for batch record automation, material handling, and compliance workflows.

stocktitan.net
2Drug Development Licensing
TypeLicensing Royalties
Description

Licensing revenue potential from proprietary drug candidates including OT-101, Deciparticle formulations, and AI platform technology. Company positions assets for partnership and M&A given industry shift toward clinical-stage programs.

financialpost.com
3Joint Venture Equity Value
TypeData Monetisation
Description

Company holds 45% stake in GMP Bio joint venture, recently valued at over $1 billion enterprise value, with plans for Hong Kong IPO. FY2025 net income of $249M driven primarily by $365.4M non-cash gain from JV revaluation.

financialpost.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details2 tiers
1PUR-E Cleanroom Robot Subscription - under ~1% of facility throughput
ModelSubscriptionBilling cadenceAnnual
Notes

Batch-record review time reduced 40-50%, manual data entry reduced 60%, documentation errors reduced 50%, batch-release cycle reduced 40-50%. One-time eBR/MES validation (21 CFR Part 11) additional.

oncotelic.com
2LIM-E Logistics Robot Agreement - 36-month with 30-day cancel notice
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Offsets ~1-1.5 porter FTE in material-handler labor, 600 lb payload capacity, 18-20 hrs/day uptime.

oncotelic.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1PDAOAI
Description

AI-augmented literature intelligence platform for precision oncology research and GMP manufacturing, indexing 28 million PubMed abstracts

oncotelic.com
+3 more records
Core offering1 text field

Oncotelic is a clinical-stage biopharmaceutical company developing first-in-class RNA therapeutics (notably OT-101, a TGF-β2 antisense oligodeoxynucleotide) and small molecule drugs against cancer and infectious diseases, alongside its proprietary Deciparticle nanomedicine delivery platform. The company also operates the PDAOAI AI-powered drug discovery and GMP manufacturing platform, which indexes approximately 28 million PubMed abstracts and integrates with autonomous robotics (PUR-E, LIM-E) to compress drug development timelines and automate cGMP manufacturing workflows for pharmaceutical manufacturers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Drug development timeline compressed from 4-7 years to under 2 years
+6 more records
Product overview1 text field

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of cancer and infectious disease treatments alongside an AI-powered drug development and manufacturing platform. The core technology is the PDAOAI platform, which includes a Knowledge Discovery module for biomedical literature analysis (~28 million PubMed abstracts) and a Robotics module integrating autonomous robots (PUR-E for cleanroom operations and LIM-E for logistics) for GMP manufacturing. The therapeutic pipeline centers on OT-101 (TGF-β2 antisense, Phase 3 for glioblastoma and pancreatic cancer), the Deciparticle nanomedicine platform (including Sapu003 IV everolimus in Phase 1b), CA4P vascular disrupting agent, Oxi4503 for leukemia, and AL-101/N2B for CNS disorders. The company operates through a 45%-owned joint venture GMP Bio comprising Sapu Bio (cGMP manufacturing) and Sapu Nano (nanomedicine development).

Product and service8 records
1PDAOAI Knowledge Discovery Platform
CategoryAI Drug Discovery Software
Description

AI-powered structural intelligence platform that indexes approximately 28 million PubMed abstracts to surface root disease drivers (genes, mechanisms, themes) rather than proximity matches. Built on Qdrant vector infrastructure. Targeted at pharmaceutical and biotech R&D teams seeking accelerated target identification and drug repurposing.

2PDAOAI GMP Manufacturing Services Platform
CategoryPharmaceutical Manufacturing Services
Description

AI-enabled manufacturing platform integrating PDAOAI software with TechForce Robotics autonomous hardware (PUR-E cleanroom robot and LIM-E logistics robot) for pharmaceutical manufacturers. Automates batch record execution, documentation, quality management, material handling, and process monitoring in cGMP environments, reducing batch-record review time by 40-50% and manual data entry by 60%.

3OT-101 (Trabedersen)
CategoryOncology Therapeutics
Description

Novel phosphorothioate antisense oligodeoxynucleotide targeting TGF-β2 mRNA for treatment of solid tumors including glioblastoma, DIPG, pancreatic cancer, colorectal cancer, and melanoma. Converts immunosuppressive M2 macrophages into pro-inflammatory M1 macrophages and synergizes with PD-1 checkpoint inhibitors. FDA Rare Pediatric Disease Designation for DIPG.

4Deciparticle Nanomedicine Platform
CategoryNanomedicine Drug Delivery
Description

Sub-100nm nanoparticle drug delivery platform that improves pharmacokinetics, tumor accumulation, and therapeutic efficacy of existing oncology drugs. Forms the foundation for multiple product candidates including Sapu003 (IV everolimus) and other candidates with IND filings expected in 2026.

5Sapu003
CategoryOncology Therapeutics
Description

Investigational intravenous Deciparticle formulation of everolimus (mTOR inhibitor) designed to treat advanced mTOR-sensitive solid tumors including HR+/HER2- breast cancer, renal cell carcinoma, neuroendocrine tumors, TSC-associated tumors, and hepatocellular carcinoma. Phase 1b trial evaluating safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity at dose levels of 5 mg/m², 7.5 mg/m², and 10 mg/m² administered IV once weekly.

6CA4P (Fosbretabulin)
CategoryOncology Therapeutics
Description

Vascular disrupting agent being developed in combination with Ipilimumab for treatment of solid tumors with focus on melanoma in adult and pediatric patients. FDA Rare Pediatric Disease Designation for stage IIB-IV melanoma.

7Oxi4503
CategoryOncology Therapeutics
Description

Second-generation vascular disrupting agent (combretastatin A1-diphosphate; CA1P) for treatment of liquid tumors with focus on childhood leukemia. FDA Rare Pediatric Disease Designation for acute myeloid leukemia (AML).

8AL-101
CategoryCNS Therapeutics
Description

Intranasal delivery of Apomorphine for treatment of Parkinson's Disease (nose-to-brain drug delivery bypassing blood-brain barrier). Also being developed for Erectile Dysfunction (targeting treatment failures of PDE5 inhibitors) and Female Sexual Dysfunction.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-08
Description

Infrastructure partnership for PDAOAI platform. Qdrant provides vector database infrastructure enabling the platform to run 28 million PubMed abstracts in production with hybrid search, payload filtering, HNSW indexing, quantization, and TurboQuant capabilities. Joint presentation at Qdrant Vector Space Day 2026 keynote.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-02
Description

Strategic partnership to commercialize PDAOAI-enabled GMP-compliant robotics platform for pharmaceutical manufacturing. The integrated platform combines Oncotelic's proprietary AI capabilities with TechForce's autonomous robots (PUR-E cleanroom robot and LIM-E logistics robot) to automate material handling, real-time monitoring, and compliance workflows in regulated manufacturing environments. Phase 1 completed with LIM-E logistics deployment; Phase 2 underway with PUR-E deployment at SAPU Bio OEB-5 sterile injectable cGMP facility.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

CRO partnership for STOP-PC Phase 2b/3 trial of OT-101 in pancreatic cancer. Cromos Pharma conducting multi-country clinical trial combining OT-101 with mFOLFIRINOX.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Phase I/II trial (ONC740 24) investigating OT-101 in combination with pembrolizumab as first-line therapy for newly diagnosed PD-L1 positive advanced non-small cell lung cancer (NSCLC). Dr. Omar Abughanimeh as Principal Investigator.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

CEO Trieu Vuong holds indirect beneficial ownership through Autotelic Inc. and spouse. Autotelic appears related to company's Korean operations including IL-2 combination therapy partner.

Strategic tierMinorTypeGTM or Marketing Partner
Description

SAPU Bioscience is a member of California Life Sciences. Company exhibits at CLS Pavilion (Booth #1525) at BIO 2026.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Joint venture advancing complementary drug candidates in oncology and rare disease therapeutics. Includes subsidiaries Sapu Bio (OEB-5 sterile injectable cGMP manufacturing) and Sapu Nano (nanomedicine development). Recently valued at over $1 billion enterprise value with plans for potential Hong Kong IPO.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage RNA therapeutics company developing stereopure antisense and RNAi oligonucleotides. Comparable as a direct RNA therapeutics peer in similar stages of clinical development with similar modality (synthetic oligonucleotides) to OT-101.

TypeDirect peer
Description

AI/computational platform-driven immuno-oncology company developing therapeutics against novel targets. Comparable to Oncotelic as a clinical-stage company combining computational target identification with immuno-oncology drug development.

TypeDirect peer
Description

AI-driven computational drug discovery platform serving pharmaceutical and biotech customers. Directly comparable to PDAOAI as a software-and-services platform applying proprietary computational methods to compress drug discovery timelines.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing bispecific immune-stimulating antibody conjugates. Comparable to Oncotelic as a clinical-stage oncology platform with novel immune-engagement mechanisms and similar pipeline maturity.

TypeDirect peer
Description

Leading commercial-stage siRNA therapeutics company with approved RNA-targeted drugs. Directly comparable as a clinical-stage-to-commercial RNA therapeutics platform targeting serious diseases with a similar underlying modality logic to Oncotelic's OT-101 antisense approach.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing combination therapies targeting the tumor microenvironment, including TGF-β and related immunosuppressive pathways. Comparable to Oncotelic's focus on overcoming immune evasion mechanisms in solid tumors.

TypeDirect peer
Description

Pioneer in antisense oligonucleotide RNA therapeutics, the same modality as Oncotelic's lead OT-101. Ionis has approved antisense drugs and a deep clinical pipeline targeting neurological, cardiovascular, and metabolic diseases, making it the most directly comparable peer in antisense RNA drug development.

TypeDirect peer
Description

AI-driven drug design company focused on accelerating small molecule discovery from concept to candidate. Directly comparable to PDAOAI's positioning as an AI platform compressing early-stage discovery timelines through proprietary computational methods.

TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput biology with machine learning to identify novel therapeutics. Comparable to Oncotelic's positioning as a technology-augmented clinical-stage biotech where AI is claimed to compress traditional development timelines.

TypeBroad incumbent
Description

Diversified biopharmaceutical company with broader oncology, immunology, and infectious disease assets. Comparable as a broader immuno-oncology and antibody therapeutics incumbent with historical connection to Oncotelic's CEO (formerly CSO/Board Director following the Igdrasol merger).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oncotelic

Biopharmaceutical Drug Developmentoncotelic.com

Oncotelic is a clinical-stage immuno-oncology company developing TGF-β antisense (OT-101), Deciparticle nanomedicines (Sapu003), and the PDAOAI AI platform for drug discovery and GMP manufacturing automation, serving pharmaceutical manufacturers and oncology patients through licensing and partnership channels.

What Oncotelic does

Oncotelic Inc. is a clinical-stage immuno-oncology company developing RNA therapeutics, small-molecule drugs, and nanomedicine delivery systems for cancer and infectious diseases, trading on the OTCQB under ticker OTLC. The lead therapeutic candidate, OT-101 (Trabedersen), is a phosphorothioate antisense oligodeoxynucleotide targeting TGF-β2 mRNA, currently in Phase 3 development for glioblastoma and Phase 2b/3 for pancreatic cancer (STOP-PC trial combining with mFOLFIRINOX). The company has secured three FDA Rare Pediatric Disease Designations (OT-101/DIPG, CA4P/melanoma, OXi4503/AML) and is advancing a Deciparticle nanomedicine platform with six nanoparticle candidates; Sapu003, an IV Deciparticle formulation of everolimus, entered a Phase 1b trial in May 2026 with the first patient dosed. Additional pipeline assets include CA4P (vascular disrupting agent), OXi4503, and AL-101/N2B intranasal nose-to-brain delivery for CNS disorders.

The company's differentiating technology layer is PDAOAI, an AI knowledge discovery platform indexing approximately 28 million PubMed abstracts refreshed daily on Qdrant vector infrastructure, using proprietary clustering, manifold folding, and shell-sampling methods (covered by PCT/US2024/057972) to identify upstream disease drivers rather than proximity matches. PDAOAI is also deployed as a robotics knowledge layer integrated with TechForce Robotics' PUR-E cleanroom robot and LIM-E logistics robot for GMP pharmaceutical manufacturing, where it automates batch-record execution through a Kebbi voice interface. The company operates through three entities: wholly-owned subsidiaries Sapu Bio and Sapu Nano, and a 45%-owned joint venture GMP Bio valued at over $1 billion enterprise value with planned Hong Kong IPO.

Oncotelic's revenue model is a mix of (i) future drug development licensing and royalty income from its therapeutic pipeline, (ii) AI-enabled GMP manufacturing services commercialized with TechForce Robotics targeting pharmaceutical manufacturers at subscription pricing tied to facility throughput, and (iii) equity value recognition from the GMP Bio JV. Currently the company has no disclosed product revenue — FY2025 net income of $249M was driven by a $365.4M non-cash JV revaluation gain — and operates as a pre-commercial biotech funded by equity rounds, most recently $12.5M in May 2026. GTM is enterprise B2B and event-driven, centered on BIO International Convention, AACR, SNO, and SITC conference presence to source partnership and licensing deals.

Oncotelic firmographics

Firmographics
Name
Oncotelic
Legal name
Oncotelic Inc.
Website
https://oncotelic.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Oncotelic is a clinical-stage immuno-oncology company developing TGF-β antisense (OT-101), Deciparticle nanomedicines (Sapu003), and the PDAOAI AI platform for drug discovery and GMP manufacturing automation, serving pharmaceutical manufacturers and oncology patients through licensing and partnership channels.
Ownership category
akta.pro rank

Oncotelic industry classification

Industry
Product category
Biopharmaceutical Drug Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Immuno-oncology therapeutics
  • Antisense RNA therapeutics
  • Nanomedicine drug delivery
  • AI drug discovery platform
  • GMP pharmaceutical manufacturing

Where Oncotelic is headquartered

Location

Headquarters

HQ city
Agoura Hills
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Oncotelic business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Manufacturing Services: Revenue from AI-powered GMP manufacturing services platform commercialized with TechForce Robotics, targeting pharmaceutical and biotech manufacturers for batch record automation, material handling, and compliance workflows.
  2. Drug Development Licensing: Licensing revenue potential from proprietary drug candidates including OT-101, Deciparticle formulations, and AI platform technology. Company positions assets for partnership and M&A given industry shift toward clinical-stage programs.
  3. Joint Venture Equity Value: Company holds 45% stake in GMP Bio joint venture, recently valued at over $1 billion enterprise value, with plans for Hong Kong IPO. FY2025 net income of $249M driven primarily by $365.4M non-cash gain from JV revaluation.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualPUR-E Cleanroom Robot Subscription - under ~1% of facility throughput
SubscriptionMulti-year contractLIM-E Logistics Robot Agreement - 36-month with 30-day cancel notice

Go-to-market motion2 records

Distribution channels5 records

Marketing channels9 records

Oncotelic product offering

Product offering

Core offering

Oncotelic is a clinical-stage biopharmaceutical company developing first-in-class RNA therapeutics (notably OT-101, a TGF-β2 antisense oligodeoxynucleotide) and small molecule drugs against cancer and infectious diseases, alongside its proprietary Deciparticle nanomedicine delivery platform. The company also operates the PDAOAI AI-powered drug discovery and GMP manufacturing platform, which indexes approximately 28 million PubMed abstracts and integrates with autonomous robotics (PUR-E, LIM-E) to compress drug development timelines and automate cGMP manufacturing workflows for pharmaceutical manufacturers.

Product overview

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of cancer and infectious disease treatments alongside an AI-powered drug development and manufacturing platform. The core technology is the PDAOAI platform, which includes a Knowledge Discovery module for biomedical literature analysis (~28 million PubMed abstracts) and a Robotics module integrating autonomous robots (PUR-E for cleanroom operations and LIM-E for logistics) for GMP manufacturing. The therapeutic pipeline centers on OT-101 (TGF-β2 antisense, Phase 3 for glioblastoma and pancreatic cancer), the Deciparticle nanomedicine platform (including Sapu003 IV everolimus in Phase 1b), CA4P vascular disrupting agent, Oxi4503 for leukemia, and AL-101/N2B for CNS disorders. The company operates through a 45%-owned joint venture GMP Bio comprising Sapu Bio (cGMP manufacturing) and Sapu Nano (nanomedicine development).

Differentiator

Problem solved

Functional benefit

Brands

  • PDAOAI: AI-augmented literature intelligence platform for precision oncology research and GMP manufacturing, indexing 28 million PubMed abstracts
  • Deciparticle
  • OT-101
  • Pet2DAO

Products and services

  • PDAOAI Knowledge Discovery Platform AI-powered structural intelligence platform that indexes approximately 28 million PubMed abstracts to surface root disease drivers (genes, mechanisms, themes) rather than proximity matches. Built on Qdrant vector infrastructure. Targeted at pharmaceutical and biotech R&D teams seeking accelerated target identification and drug repurposing.
  • PDAOAI GMP Manufacturing Services Platform AI-enabled manufacturing platform integrating PDAOAI software with TechForce Robotics autonomous hardware (PUR-E cleanroom robot and LIM-E logistics robot) for pharmaceutical manufacturers. Automates batch record execution, documentation, quality management, material handling, and process monitoring in cGMP environments, reducing batch-record review time by 40-50% and manual data entry by 60%.
  • OT-101 (Trabedersen) Novel phosphorothioate antisense oligodeoxynucleotide targeting TGF-β2 mRNA for treatment of solid tumors including glioblastoma, DIPG, pancreatic cancer, colorectal cancer, and melanoma. Converts immunosuppressive M2 macrophages into pro-inflammatory M1 macrophages and synergizes with PD-1 checkpoint inhibitors. FDA Rare Pediatric Disease Designation for DIPG.
  • Deciparticle Nanomedicine Platform Sub-100nm nanoparticle drug delivery platform that improves pharmacokinetics, tumor accumulation, and therapeutic efficacy of existing oncology drugs. Forms the foundation for multiple product candidates including Sapu003 (IV everolimus) and other candidates with IND filings expected in 2026.
  • Sapu003 Investigational intravenous Deciparticle formulation of everolimus (mTOR inhibitor) designed to treat advanced mTOR-sensitive solid tumors including HR+/HER2- breast cancer, renal cell carcinoma, neuroendocrine tumors, TSC-associated tumors, and hepatocellular carcinoma. Phase 1b trial evaluating safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity at dose levels of 5 mg/m², 7.5 mg/m², and 10 mg/m² administered IV once weekly.
  • CA4P (Fosbretabulin) Vascular disrupting agent being developed in combination with Ipilimumab for treatment of solid tumors with focus on melanoma in adult and pediatric patients. FDA Rare Pediatric Disease Designation for stage IIB-IV melanoma.
  • Oxi4503 Second-generation vascular disrupting agent (combretastatin A1-diphosphate; CA1P) for treatment of liquid tumors with focus on childhood leukemia. FDA Rare Pediatric Disease Designation for acute myeloid leukemia (AML).
  • AL-101 Intranasal delivery of Apomorphine for treatment of Parkinson's Disease (nose-to-brain drug delivery bypassing blood-brain barrier). Also being developed for Erectile Dysfunction (targeting treatment failures of PDE5 inhibitors) and Female Sexual Dysfunction.

Quantifiable outcome

  • Drug development timeline compressed from 4-7 years to under 2 years
  • +6 more outcomes

Companies that use Oncotelic

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Oncotelic technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Oncotelic partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, flagship and minor.

  • QdrantcoreTechnology or Integration · 8 June 2026Infrastructure partnership for PDAOAI platform. Qdrant provides vector database infrastructure enabling the platform to run 28 million PubMed abstracts in production with hybrid search, payload filtering, HNSW indexing, quantization, and TurboQuant capabilities. Joint presentation at Qdrant Vector Space Day 2026 keynote.
  • TechForce RoboticsflagshipStrategic or Co-development Partner · 2 April 2026Strategic partnership to commercialize PDAOAI-enabled GMP-compliant robotics platform for pharmaceutical manufacturing. The integrated platform combines Oncotelic's proprietary AI capabilities with TechForce's autonomous robots (PUR-E cleanroom robot and LIM-E logistics robot) to automate material handling, real-time monitoring, and compliance workflows in regulated manufacturing environments. Phase 1 completed with LIM-E logistics deployment; Phase 2 underway with PUR-E deployment at SAPU Bio OEB-5 sterile injectable cGMP facility.
  • Cromos PharmacoreImplementation/ SI/ Consulting PartnerCRO partnership for STOP-PC Phase 2b/3 trial of OT-101 in pancreatic cancer. Cromos Pharma conducting multi-country clinical trial combining OT-101 with mFOLFIRINOX.
  • Nebraska MedicinecoreImplementation/ SI/ Consulting PartnerPhase I/II trial (ONC740 24) investigating OT-101 in combination with pembrolizumab as first-line therapy for newly diagnosed PD-L1 positive advanced non-small cell lung cancer (NSCLC). Dr. Omar Abughanimeh as Principal Investigator.
  • Autotelic Inc.minorStrategic or Co-development PartnerCEO Trieu Vuong holds indirect beneficial ownership through Autotelic Inc. and spouse. Autotelic appears related to company's Korean operations including IL-2 combination therapy partner.
  • California Life SciencesminorGTM or Marketing PartnerSAPU Bioscience is a member of California Life Sciences. Company exhibits at CLS Pavilion (Booth #1525) at BIO 2026.
  • GMP Bio (45% Owned JV)flagshipStrategic or Co-development PartnerJoint venture advancing complementary drug candidates in oncology and rare disease therapeutics. Includes subsidiaries Sapu Bio (OEB-5 sterile injectable cGMP manufacturing) and Sapu Nano (nanomedicine development). Recently valued at over $1 billion enterprise value with plans for potential Hong Kong IPO.

Scale indicators10 records

Recent moves8 records

Expansion highlights7 records

Oncotelic competitors and assessment

Company assessment

Direct peers

  • Wave Life Sciences: Clinical-stage RNA therapeutics company developing stereopure antisense and RNAi oligonucleotides. Comparable as a direct RNA therapeutics peer in similar stages of clinical development with similar modality (synthetic oligonucleotides) to OT-101.
  • Compugen: AI/computational platform-driven immuno-oncology company developing therapeutics against novel targets. Comparable to Oncotelic as a clinical-stage company combining computational target identification with immuno-oncology drug development.
  • Schrödinger Inc. AI-driven computational drug discovery platform serving pharmaceutical and biotech customers. Directly comparable to PDAOAI as a software-and-services platform applying proprietary computational methods to compress drug discovery timelines.
  • Alnylam Pharmaceuticals: Leading commercial-stage siRNA therapeutics company with approved RNA-targeted drugs. Directly comparable as a clinical-stage-to-commercial RNA therapeutics platform targeting serious diseases with a similar underlying modality logic to Oncotelic's OT-101 antisense approach.
  • Ionis Pharmaceuticals: Pioneer in antisense oligonucleotide RNA therapeutics, the same modality as Oncotelic's lead OT-101. Ionis has approved antisense drugs and a deep clinical pipeline targeting neurological, cardiovascular, and metabolic diseases, making it the most directly comparable peer in antisense RNA drug development.
  • Exscientia: AI-driven drug design company focused on accelerating small molecule discovery from concept to candidate. Directly comparable to PDAOAI's positioning as an AI platform compressing early-stage discovery timelines through proprietary computational methods.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning to identify novel therapeutics. Comparable to Oncotelic's positioning as a technology-augmented clinical-stage biotech where AI is claimed to compress traditional development timelines.

Emerging players

  • Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing bispecific immune-stimulating antibody conjugates. Comparable to Oncotelic as a clinical-stage oncology platform with novel immune-engagement mechanisms and similar pipeline maturity.
  • Arcus Biosciences: Clinical-stage immuno-oncology company developing combination therapies targeting the tumor microenvironment, including TGF-β and related immunosuppressive pathways. Comparable to Oncotelic's focus on overcoming immune evasion mechanisms in solid tumors.

Broad incumbents

  • Sorrento Therapeutics: Diversified biopharmaceutical company with broader oncology, immunology, and infectious disease assets. Comparable as a broader immuno-oncology and antibody therapeutics incumbent with historical connection to Oncotelic's CEO (formerly CSO/Board Director following the Igdrasol merger).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Oncotelic social profiles

Digital presence

Oncotelic financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oncotelic leadership team

Management profile

Number of profiles

Profiles5 records

Oncotelic subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Oncotelic funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oncotelic M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncotelic

What does Oncotelic do?

Oncotelic is a clinical-stage biopharmaceutical company developing first-in-class RNA therapeutics (notably OT-101, a TGF-β2 antisense oligodeoxynucleotide) and small molecule drugs against cancer and infectious diseases, alongside its proprietary Deciparticle nanomedicine delivery platform. The company also operates the PDAOAI AI-powered drug discovery and GMP manufacturing platform, which indexes approximately 28 million PubMed abstracts and integrates with autonomous robotics (PUR-E, LIM-E) to compress drug development timelines and automate cGMP manufacturing workflows for pharmaceutical manufacturers.

Is Oncotelic a public or private company?

Oncotelic is a public company. It is classified as public and is currently operating.

When was Oncotelic founded?

Oncotelic was founded in 2020. It employs 51 to 100 people.

Where is Oncotelic based?

Oncotelic is headquartered in Agoura Hills, United States, in the North America region.

How does Oncotelic make money?

Three revenue lines are on record. Pharmaceutical Manufacturing Services are the primary driver. The others are drug Development Licensing and joint Venture Equity Value.

Who are Oncotelic's main competitors?

Direct peers on record are Wave Life Sciences, Compugen, Schrödinger Inc., Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Exscientia and Recursion Pharmaceuticals. Emerging players are Bolt Biotherapeutics and Arcus Biosciences. Sorrento Therapeutics is listed as a broad incumbent.

Does Oncotelic have an API?

No public API is recorded for Oncotelic.

What industry is Oncotelic in?

Oncotelic's product category is Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialOncotelic Advances PLA From Published Liver Cancer Findings Toward 100 Billion Protein VectorsOncotelic Therapeutics is advancing its PDAOAI drug discovery engine, using its Partitioned Literature Aggregation (PLA) algorithm to uncover clues in published research. A liver-cancer study published in Biomedicines on October 23, 2026, provided a concrete example, connecting PLA-guided investigation with a four-gene survival signature validated in an independent patient cohort. The company is targeting a 100-billion-vector protein program.TradingViewOncotelic Therapeutics Presents PLA Framework and Four-Gene Liver Cancer SignatureOncotelic Therapeutics presented its Partitioned Literature Aggregation (PLA) framework and a four-gene mTOR-related signature linked to patient outcomes in liver cancer at the 22nd Drug Discovery Strategic Summit on October 22, 2026. The company plans to expand PLA using autonomous AI agents targeting 100 billion protein-related vectors.Stock TitanOncotelic Opens Free BIO REBOOT RegistrationOncotelic Therapeutics opened free registration for its BIO REBOOT collaboration through its PDAOAI drug discovery platform, inviting scientists and biotech founders. The company will present at Drug Discovery 2026, including a hepatocellular carcinoma case study. Selected projects may receive startup funding and development support.Financial PostNightfood Holdings Highlights Robotics Progress in Shareholder UpdateNightfood Holdings, doing business as TechForce Robotics, updated shareholders on robotics progress, including a supply agreement with Taiwan's Jiun Jiang Enterprise and a Phase 2 collaboration with Oncotelic Therapeutics. The company also signed an LOI with NBR Intelligence for up to 5,000 robotic systems and established an independent board majority. It plans to continue advancing commercial opportunities and strengthening governance for a potential national exchange listing.Stock TitanNightfood Holdings Evaluates Up to ~100K Sq. Ft. CapacityNightfood Holdings, doing business as TechForce Robotics, reported a shareholder update on robotics progress, including a supply agreement with Taiwan's Jiun Jiang Enterprise evaluating up to 100,000 square feet of manufacturing capacity. The company also advanced its pharmaceutical automation program with Oncotelic Therapeutics and signed an LOI with NBR Intelligence for up to 5,000 robotic systems. It plans to continue advancing these opportunities while strengthening governance for a potential national exchange listing.Markets DailyOncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest UpdateOncotelic Therapeutics reported a 99.8% drop in short interest, falling to 16 shares as of August 14 from 9,551 on July 30, with 0.0% of shares sold short. The stock traded at $0.03 on Tuesday, down $0.00, with a market capitalization of $14.84 million.GlobeNewswireOncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6thOncotelic Therapeutics Inc. announced that CEO Dr. Vuong Trieu will present at the OTCQB Virtual Investor Conference on August 6th, 2026, a live interactive online event where investors can ask questions in real-time. The announcement also highlighted recent company progress including advancement of Phase 1b IV Everolimus to the next dose cohort, initiation of European clinical expansion, peer-reviewed publications validating the Deciparticle platform, and establishment of clinical-stage GMP manufacturing capabilities. The company is a clinical-stage biotechnology firm focused on developing oncology therapies using precision medicine, RNA therapeutics, AI drug discovery, and nanomedicine delivery technologies.GlobeNewswireOncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6thOncotelic Therapeutics announced that CEO Dr. Vuong Trieu will present live at the OTCQB Virtual Investor Conference on August 6th, 2026. The company highlighted recent advances, including Phase 1b IV Everolimus advancing to the next dose cohort and European clinical expansion.BioSpaceOncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)Oncotelic and Sapu Nano published a peer-reviewed study in Biomedicines validating Deciparticle technology for Sapu003, an IV everolimus formulation. The study covers ADME, pharmacokinetics, toxicology, and cGMP manufacturing, supporting ongoing Phase 1b clinical trials in advanced solid tumors.FinancialContent Business PageBioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Preclinical Data Supporting IV Cancer TherapyOncotelic Therapeutics and Sapu Nano announced publication of peer-reviewed preclinical data in Biomedicines for Sapu003, an intravenous Deciparticle formulation of everolimus designed for cancer therapy. The published findings cover ADME, pharmacokinetics, tissue distribution, GLP toxicology, and cGMP manufacturing data, supporting the ongoing Phase 1 clinical evaluation in patients with advanced solid tumors. The company reports the formulation reduces gastrointestinal drug exposure compared with oral everolimus and showed no treatment-related gastric pathology in repeat-dose GLP toxicology studies.